Insider buying last 90 days
No open-market insider purchases were filed for GMAB in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GMAB insider filing, plotted on the chart in Gekko.Open GMAB in Gekko
Gekko Brief
AI summaryGenmab hits a new 52-week high this week, trading as high as $35.66, with shares last closing at $35.36. The move follows commentary from investor relations head Andrew Carlsen that the company expects a pivotal fourth quarter, with Phase III readouts planned for three late-stage oncology programs viewed as potential first-in-class opportunities. Separately, the company granted 13,794 restricted stock units and 13,331 warrants to employees as part of its long-term incentive programs, and at least one outside assessment described the stock as fairly valued following its recent gain, citing a P/E of 26.5x near the biotech sector average.
At $35.36, the stock sits above both its 50-day average of $32.15 and 200-day average of $29.56, with the shorter average above the longer one, a trend picture that remains supportive. The GekkoIndex reads 47.5, placing it in the Neutral zone. Price stands 12.7% above Gekko Fair Value of $31.38.
The next earnings date falls on 5 November, 37 days out and beyond a typical 20-day holding window. No insider, Congress, or unusual options activity appears in the current windows. Seasonality over the next 20 trading days has averaged +0.3% across 5 years, rising in 2 of them. With three Phase III readouts anticipated in the fourth quarter, near-term newsflow around those trial results bears watching.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Genmab price vs fair value
Close $35.36200-day averageGekko Fair Value $31.38
Genmab quick facts
- Market cap
- $21.71B
- P/E ratio
- 28
- Forward P/E
- 15.1
- EPS, TTM
- $1.26
- Revenue, TTM
- $4.13B
- Profit margin
- 19.1%
- Dividend yield
- —
- Beta
- 0.70
- Volume
- 2.79M avg 2.07M
- 1-year return
- +22.6%
- Typical daily move
- ±2.3%
- Typical 20-day move
- ±6.7%
- 50-day average
- $32.15
- 200-day average
- $29.56
- Next earnings
- Nov 5
- Shares outstanding
- 614.9M
Genmab swing-trade checklist
Genmab scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $35.36 is above the 50-day ($32.15) and 200-day ($29.56) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
47.5, Neutral
Reading 47.5 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
12.7% above
Price is 12.7% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+0.3% on average
From this point in the calendar, the next 20 trading days averaged +0.3% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Genmab stock chart and price history
Genmab closed at $35.36 on Sep 28, 2026, +22.6% over the past year, inside a 52-week range of $23.62 to $35.70.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +3.7%
- 3 months
- +35.9%
- 6 months
- +36.9%
- 1 year
- +22.6%
The full GMAB chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GMAB in Gekko
Follow Genmab through every session
Put GMAB on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GMAB in GekkoFree for 7 days. No credit card required.
About Genmab
Genmab works in biopharmaceuticals, focusing on discovering and developing antibody-based treatments, mainly for cancer along with a handful of other serious conditions. It is known for its marketed antibody therapies, including a treatment for multiple myeloma and related blood cancers, one for thyroid eye disease, one used in chronic lymphocytic leukemia and multiple sclerosis, another for certain gastric, esophageal and lung cancers, and one aimed at cervical and ovarian cancers and other solid tumors.
Beyond its approved products, Genmab runs a wide pipeline of experimental antibodies at various clinical stages, targeting solid tumors and blood cancers, alongside roughly twenty early pre-clinical programs. Much of this work is carried out through partnerships rather than alone, with agreements covering commercialization and co-development, mRNA-based antibody research, and other joint development deals with several pharmaceutical and biotech partners.
Genmab was established in 1999 and is headquartered in Copenhagen, Denmark. Its shares trade under the ticker GMAB.
- Sector
- Health technology
- Website
- genmab.com
Genmab GekkoIndex: the smart money zone
Genmab’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 47.5, in the Neutral zone, down 1.3 points over five sessions.
47.5Neutral
Down 1.3 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 47 | −0.6% | +1.0% | ||
| Accumulation | 218 | +0.5% | +1.9% | ||
| Neutral (current zone) | 323 | +0.1% | −0.1% | ||
| Distribution | 37 | +0.8% | +3.2% | ||
| Selling | 0 | Not available | |||
Average GMAB share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the GMAB price, zone by zone.Track GMAB in Gekko
Is Genmab stock overvalued? Gekko Fair Value
Genmab trades 12.7% above Gekko Fair Value of $31.38, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Genmab shares are worth, recalculated every trading day.
$31.38
Gekko Fair Value, Sep 29, 2026
12.7% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open GMAB in Gekko
Genmab insider and Congress trading
No open-market insider purchases were filed for Genmab, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GMAB were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GMAB, plotted on the chart in Gekko.Open GMAB in Gekko
Buybacks
Genmab has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2026
- $96.36M
- As a share of market cap
- 0.44%
- Trailing four quarters
- $526.7M
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold GMAB.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Genmab earnings: next date and track record
Genmab reports on Nov 5, 2026 (37 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 5, 2026
37 days away
- EPS estimate
- $0.37
- Revenue estimate
- $1.21B
5 of 8reports beat the EPS estimate
±4.4%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Genmab First Half 26 earnings call: Management presented strong financial and pipeline progress. Revenue grew 25% year-over-year, driven by product momentum (particularly Epkinly and Darzalex) and integration of Merus. Epkinly (EPKINLY) sales increased 48% to $312M for H1, showing accelerated uptake in community settings and across indications. Key pipeline developments: positive Phase III EPCORE DLBCL-4 PFS results for epcoritamab combinations; European approval for TEPKINLY plus lenalidomide and rituximab in second-line FL; initiation of two Phase III petosemtamab trials in colorectal cancer (frontline and second-line) and ongoing Phase III trials in head and neck cancer; Rina-S (fotivda?) program progressing with Phase II/III readouts planned in PROC and endometrial/ovarian expansion; strong conviction in petosemtamab as best-in-class EGFR bispecific vs amivantamab. Management emphasized disciplined capital allocation, integration of Merus, tax rate dynamics due to integration, and increased adjusted operating profit by 18%. Guidance updated for 2026 (details cut off in transcript) and effective tax rate expected to normalize in 12-18 months. Q&A covered timing and design of multiple Phase III readouts (EPKINLY frontline DLBCL interim in Q4; Peto frontline interim in Q4; Peto second-line OS readout in Q1 2027; Rina-S Phase II/III PROC readouts in Q4), differentiation vs competitors, IP/patent strategy, commercialization readiness, and trial enrollment/power/upsize decisions. Tone: confident and positive with measured caution around timing and data maturity.
- Guidance
- Updated 2026 financial guidance discussed; transcript cuts off before specific updated numbers are included. Management updated 2026 guidance but no explicit numeric guidance is present in provided segments.
- Risks flagged
- Possible timing delays for trial readouts (some readouts shifted, e.g., petosemtamab second-line OS to Q1 2027); uncertainties in overall survival maturity for DLBCL-4; competitive landscape (amivantamab, J&J, others in EGFR bispecifics and folate receptor ADCs); regulatory uncertainty regarding which trial will serve as confirmatory; tax rate fluctuations during Merus integration; general clinical and development risks noted in opening operator remarks.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.54 est $0.37 | $1.16B est $1.12B | +6.8% |
| May 7, 2026 | $0.13 est $0.19 | $896.0M est $905.8M | −5.2% |
| Feb 17, 2026 | $0.21 est $0.37 | $1.06B est $1.07B | −2.9% |
| Nov 6, 2025 | $0.65 est $0.45 | $1.02B est $1.01B | −1.8% |
| Aug 7, 2025 | $0.54 est $0.34 | $924.8M est $952.6M | −0.4% |
| May 8, 2025 | $0.31 est $0.23 | $726.0M est $755.5M | −6.0% |
| Feb 12, 2025 | $0.84 est $0.28 | $891.4M est $791.9M | +10.7% |
| Nov 6, 2024 | $0.29 est $0.33 | $815.2M est $809.6M | +1.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Genmab stock forecast and analyst price targets
Analysts’ average 12-month price target for Genmab is $39.14, +10.7% from the last close, from 9 firms rating the stock in the last 90 days.
$39.14consensus 12-month target, +10.7% from the last close
Now $35.36Avg $39.14
Low $35High $43
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 14 | H.C. Wainwright | $40 | +13.1% |
| Aug 12 | Truist Financial | — | — |
| Aug 11 | William Blair | — | — |
| Aug 7 | Truist Financial | $40 | +13.1% |
| Aug 7 | Jefferies | — | — |
−0.1%average 20-day move after past Neutral readings
+0.3%average move over the next 20 trading days in the last 5 years
±2.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Genmab seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Genmab averaged +0.3% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +5.3% | 3 of 5 |
| Next 10 trading days | +3.5% | 3 of 5 |
| Next 15 trading days | +0.7% | 3 of 5 |
| Next 20 trading days | +0.3% | 2 of 5 |
| Next 30 trading days | +3.9% | 2 of 5 |
For scale, GMAB’s typical 20-trading-day move in either direction is about 6.7%.
Genmab market cap and key statistics
Genmab’s market cap is $21.71B, with a P/E ratio of 28 and revenue of $4.13B over the last twelve months.
Valuation
- Market cap
- $21.71B
- P/E ratio
- 28
- Forward P/E
- 15.1
- EPS, TTM
- $1.26
- Gekko Fair Value
- $31.38
Trading
- Volume
- 2.79M
- Avg volume, 20 days
- 2.07M
- 52-week high
- $35.70
- 52-week low
- $23.62
- Shares outstanding
- 614.9M
Financials
- Revenue, TTM
- $4.13B
- Profit margin
- 19.1%
- Return on equity
- 14%
- Quarterly earnings growth, YoY
- −9.4%
Risk and income
- Beta
- 0.70
- Typical daily move
- ±2.3%
- Typical 20-day move
- ±6.7%
Genmab stock news this week
Coverage of Genmab this week reads positive: 6 positive, 5 neutral and 0 negative headlines.
- Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4MarketBeat, Sep 26
- Genmab stock at DKK 2,277 on September 25, 2026, up 0.40 percentAD HOC NEWS, Sep 26
- Genmab Grants New Employee Restricted Stock Units and WarrantsThe Globe and Mail, Sep 26
- Genmab (CPSE:GMAB) Stock Looks Fairly Valued Following Its 25% GainWebull, Sep 25
- Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High – What’s Next?Defense World, Sep 25
- Genmab stock gains 0.8 percent ahead of the openAD HOC NEWS, Sep 24
Genmab stock FAQ
What is Genmab’s market cap?
Genmab’s market cap is $21.71B at the Sep 28, 2026 close of $35.36, with 614.9M shares outstanding. The shares trade on a P/E ratio of 28.
What is the Genmab stock forecast?
The consensus analyst 12-month price target for Genmab is $39.14, +10.7% from the last close. Of the 9 firms that rated the stock in the last 90 days, 8 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Genmab stock overvalued or undervalued?
On Gekko’s estimate Genmab is overvalued: the Sep 28, 2026 close of $35.36 is 12.7% above Gekko Fair Value of $31.38. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Genmab report earnings next?
Genmab is expected to report on Nov 5, 2026 (37 days away). Analysts expect earnings of $0.37 per share on revenue of $1.21B. Genmab beat the earnings estimate in 5 of its last 8 reports, moving 4.4% on average across the report.
What is Genmab’s 52-week high and low?
Genmab’s 52-week high is $35.70 and its 52-week low is $23.62; it closed at $35.36 on Sep 28, 2026, +22.6% over the past year. Over the last five years the shares peaked at $47.50 on Dec 2, 2022.
Is Genmab stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Genmab the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.